TP53 and posterior cortical atrophy: TP53 genetic alterations were reported in 3–12.5% of cases which were considered late events and associated with metastatic castrate-resistant prostate cancer (mCRPC) [34]; however, other studies reported an inactivation of TP53 at a high frequency in primary as well as metastatic castration-naïve PCa [35].